Clinical Trial Update: T Cell Receptor Immunotherapy Targeting HPV-16 E6 for HPV-Associated Cancers [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating a T cell receptor immunotherapy targeting HPV-16 E6 in HPV-associated cancers has completed testing with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anal Cancer
• Cervical Cancer
• Oropharyngeal Cancer
• Penile Cancer
• Vaginal Cancer

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Vaginal Cancer, Cervical Cancer | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2017-08-02